FIXX - Homology Medicines unveils plans to start three gene therapy programs this year

Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is for Phenylketonuria ((PKU)).Additionally, the company plans to name another development candidate focused on a new therapeutic indication during this year.Last year in November, the dose-escalation portion of the Phase 1/2 study evaluating its gene therapy (HMI-102) for PKU, showed increased ALTs (indicative of liver damage) in mid- and high-dose cohorts, that were managed with increased steroids when necessary.Company Presentation Jan 2021.

For further details see:

Homology Medicines unveils plans to start three gene therapy programs this year